Nonsense - Pharmaceuticals

Benefiting from local R&D demand:

• $Regeneron Pharma(REGN.US)
• Logic: Strong in-house R&D engine, specializing in ophthalmology, immunology, and oncology. Its independent innovation capability becomes an advantage amid the trend of reducing external dependencies.
• Highlights: Strong sales of star products Eylea and Dupixent, with a deep R&D.
• $Vertex Pharma(VRTX.US)
• Logic: Absolute monopoly in the cystic fibrosis (CF) field, with ample cash flow. Actively expanding into non-CF areas (e.g., pain, kidney diseases).
• Highlights: The first gene-editing therapy in collaboration with CRISPR Therapeutics has been approved, representing future technological direction.
• $Amgen(AMGN.US)
• Logic: Among large pharmaceutical companies, it possesses strong biologics R&D and manufacturing capabilities. Its obesity drug MariTide is seen as a potential competitor to Eli Lilly and Novo Nordisk.
• Highlights: Strengthened inflammatory disease product line after acquiring Horizon, with in-house manufacturing capabilities reducing supply chain risks.

Benefiting from production reshoring:

• $Thermo Fisher Scentific(TMO.US)
• Logic: A global scientific services giant providing equipment, consumables, and CDMO services from R&D to production. It is the "shovel seller" of biotech infrastructure.
• Highlights: Regardless of policy changes, its indispensable position in the industry remains solid.
• $Novo Nordisk AS(NVO.US) Logic: A top global CDMO, specializing in biologics, cell and gene therapy, and oral/injectable manufacturing. Benefits from production reshoring.
• $Danaher(DHR.US)
• Logic: Its subsidiary Cytiva is a leading brand in bioprocessing equipment and consumables. Pharmaceutical companies expanding capacity will inevitably procure its products.
• Highlights: Diversified and stable business, less affected by economic cycles.

Clinical trial and data service leaders:

• $IQVIA(IQV.US)
• Logic: One of the world's largest CROs (Contract Research Organizations), providing clinical trial management, data analysis, and compliance consulting. The stricter the FDA's data standards, the more its value is highlighted.
• Highlights: Possesses an irreplaceable real-world data (RWD) repository.
• $Charles River Laboratorie(CRL.US)
• Logic: Focuses on preclinical research (drug discovery, safety evaluation), the forefront of drug development. Localized innovative drug R&D will increase its demand.
• Highlights: Early-stage offerings have pricing power and high barriers to entry.
• $ROCHE HOLDINGS AG(RHHVF.US)
• Logic: Dual core in diagnostics and pharmaceuticals. Diagnostics are critical for supply chain security, while the pharmaceutical division has a strong foundation in neuroscience and oncology.
  · Highlights: Extensive collaboration history with Chinese pharmaceutical companies, potentially serving as a bridge for "workaround" partnerships.

Technology platform companies:

• $BioNTech SE(BNTX.US)
• Logic: Leader in mRNA technology platforms, actively developing applications beyond COVID-19 vaccines, such as cancer vaccines.
• Highlights: Headquartered in Germany, with successful collaboration precedents in China (e.g., Fosun Pharma), a replicable model for other pipelines.
• $Genmab A/S(GMAB.US)
• Logic: Denmark's "Antibody King," with unique ADC (Antibody-Drug Conjugate) platform technology.
• Highlights: Its platform is highly attractive to Chinese pharmaceutical companies seeking technological upgrades, with abundant licensing opportunities.
• $Argenx(ARGX.US)
• Logic: Belgian immunology company; its FcRN inhibitor Vyvgart has proven its innovative capabilities.
• Highlights: Represents the rise of mid-sized European biotech innovators, with pipeline revaluation potential.

Investment strategy recommendations:

• Diversify: Avoid betting on a single company; build a portfolio by industry role (R&D, manufacturing, services).
  Focus on small/mid-caps: Beyond the leaders, consider biotech ETFs to capture U.S. small/mid-cap innovators with M&A potential.
• Dynamic tracking: Monitor the final version of U.S. executive orders, FDA guidelines, and Chinese pharma responses (e.g., European JVs, plant construction), as these will be key stock price drivers.
• Valuation awareness: Some beneficiaries may have already priced in expectations; assess valuation rationality before entry.
• Risk reminder: Policy uncertainty remains the biggest variable. Escalating geopolitical tensions could spill over to European firms. Always assess personal risk tolerance before investing.